C.4	Coagulation factors for haemophilia – review of square box alternatives – EML and EMLc
Draft recommendation	☒ Recommended ☒ Not recommended Justification: The review application submitted by World Federation of Haemophilia dose not follows the exact format of the expert committee application. The proposal contains several different suggestions in one application and this has caused some challenges For review process. Some suggestions are approved while others not recommended. Summary of recommendations: 1. Do not remove dextran from the List. Dextran is the only plasma substitute on the list. 2. Do not add desmopressin to the "plasma substitute" section. Desmopressin cannot be used as plasma substitute. 3. Bypassing agents and bispecific MAb may be needed for very small portion s of hemophilia patients (already as a rare disease). They are not therapeutic alternative to coagulation factors. They are very expensive and not widely available. Do not add bypassing agents and bispecific MAb to the EML at this stage. 4. Add desmopressin as therapeutic alternative to factor VIII to the list for treatment of patients with mild to moderate hemophilia A. 5. Add coagulation factor IX complex to the list as therapeutic alternative to factor IX (only if purified factor IX is not available).
Does the proposed medicine address a relevant public health need?	☒ Yes ☐ No ☐ Not applicable Comments:
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process)	☒ Yes ☐ No ☐ Not applicable Comments:
Does adequate evidence exist for the safety/harms associated with the proposed medicine? (this may be evidence included in the application, and/or additional evidence identified during the review process)	☒ Yes ☐ No ☐ Not applicable Comments:

Are there any adverse effects of concern, or that may require special monitoring?	☒ Yes ☐ No ☐ Not applicable Comments: for some medicines
Are there any special requirements for the safe, effective and appropriate use of the medicines? (e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)	☒ Yes ☐ No ☐ Not applicable Comments: for some medicines
Are there any issues regarding cost, cost-effectiveness, affordability and/or access for the medicine in different settings?	☒ Yes ☐ No ☐ Not applicable Comments: Especially for proposed bypassing medicines and MAbs.
Are there any issues regarding the registration of the medicine by national regulatory authorities? (e.g. accelerated approval, lack of regulatory approval, off-label indication)	☒ Yes ☐ No ☐ Not applicable Comments: for some medicines
Is the proposed medicine recommended for use in a current WHO guideline? (refer to: https://www.who.int/publications/who-guidelines)	☒ Yes ☒ No ☐ Not applicable Comments: some medicines are on the WHO guidelines